Where does James Abell work?

James Abell is Senior Adviser at Abingworth.

What does James Abell invest in?

James Abell invests in Biotech.

What boards does James Abell sit on?

James Abell holds tracked board seats at Avillion, Chroma Therapeutics, Clinical Designs, SFJ Pharmaceuticals, Syntaxin.

James Abell

Investor

Senior Adviser at Abingworth

Find your path to James

51 people in our graph can introduce you to James.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Carlos Paya to introduce you to James

You →Carlos · together at Abingworth →James

Ask Jamie Chen to introduce you to James

You →Jamie · 11 people · together at Abingworth →James

Your email: the people you already email who know James
2nd- and 3rd-degree connections: people you know who worked, studied or invested with James
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

James Abell served as Abingworth's CFO for over 20 years, overseeing finance, compliance, administration and investment matters with a focus on start-up companies, before retiring in 2019. He was previously CFO of biotech start-up Prolifix, trained as a Chartered Accountant with KPMG, and holds a degree in Biology with Chemistry from the University of Southampton. He now works as a Senior Adviser on clinical co-development deals.

Invests in

Biotech

Investments

Board seats

AvillionChroma TherapeuticsClinical DesignsSFJ PharmaceuticalsSyntaxin

Per the firm's website.

Leave your own feedback

Colleagues at Abingworth

Alex Asquith

Counsel at Abingworth

Amit Khasgiwala

Investment Professional at Innovatus Capital Partners

Andrew Sinclair

Managing Director, Head of Publics & Late Stage at Abingworth

Ankur Shah

Vice President, CCD at Abingworth

Anna Slezak

Senior Associate at Abingworth

Bali Muralidhar

Global Head of Life Sciences & CIO at Abingworth

Carlos Paya

Venture Partner at Ysios Capital

David Leathers

General Partner at Abingworth

Frequently asked questions

Who is James Abell?: James Abell served as Abingworth's CFO for over 20 years, overseeing finance, compliance, administration and investment matters with a focus on start-up companies, before retiring in 2019. He was previously CFO of biotech start-up Prolifix, trained as a Chartered Accountant with KPMG, and holds a degree in Biology with Chemistry from the University of Southampton. He now works as a Senior Adviser on clinical co-development deals.
Where does James Abell work?: James Abell is Senior Adviser at Abingworth.
What does James Abell invest in?: James Abell invests in Biotech.
What boards does James Abell sit on?: James Abell holds tracked board seats at Avillion, Chroma Therapeutics, Clinical Designs, SFJ Pharmaceuticals, Syntaxin.